Coherus BioSciences (CHRS) Reports In-Line Q4 EPS
Tweet
Share
E-mailGet Alerts CHRS Hot Sheet
Price: $1.50 +1.35%
EPS Growth %: +23.5%
Financial Fact:
Interest expense: -3.14M
Today's EPS Names:
CGEH, NAKA, APOG, More
EPS Growth %: +23.5%
Financial Fact:
Interest expense: -3.14M
Today's EPS Names:
CGEH, NAKA, APOG, More
Join SI Premium – FREE
Coherus BioSciences (NASDAQ: CHRS) reported Q4 EPS of ($0.34), in-line with the analyst estimate of ($0.34). Revenue for the quarter came in at $12.7 million versus the consensus estimate of $14.16 million.
For earnings history and earnings-related data on Coherus BioSciences (CHRS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Gulfport Energy and Mobility Global to join S&P SmallCap 600
- Tractor Supply and Starlink team up to expand rural broadband via 4-H
- AES stockholders approve $10.7 billion takeover by GIP and EQT
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
